Phase II Study of Alvocidib (NSC 649890, IND 46,211, Flavopiridol) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias

Trial Profile

Phase II Study of Alvocidib (NSC 649890, IND 46,211, Flavopiridol) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2015

At a glance

  • Drugs Alvocidib (Primary) ; Cytarabine (Primary) ; Mitoxantrone (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Oct 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 24 Jun 2012 Results published in Haematologica.
    • 19 Jul 2011 Status changed from completed to discontinued as reported by CLinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top